News

6 New Angioedema Centers Now Part of ACARE Global Network

To continue to improve patient access to top-shelf angioedema care, the global network of Angioedema Centers of Reference and Excellence (ACARE) added six centers last year, two of them in Hong Kong. More centers are expected to join the ACARE network this year — more than a dozen…

Early Trial Supporting 3-month Dosing With STAR-0215 for HAE

A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely led to rapid and sustained inhibition of the kallikrein protein in healthy adults, according to preliminary data from a Phase 1a trial. “STAR-0215 has shown early proof of concept for…

Israel Approves Oral Therapy Orladeyo to Prevent HAE Attacks

Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE)  in Israel can now receive once-daily Orladeyo (berotralstat) to prevent HAE-related swelling attacks. The decision to approve the medication by the Israeli Ministry of Health follows similar decisions in Canada and Switzerland, as well as…